Sobi® Partners with Enable Injections to Innovate Treatment Solutions
Sobi® and Enable Injections, Inc. have recently established a significant international partnership aimed at enhancing healthcare by providing innovative treatment options. This collaboration is centered on the enFuse® Injector, an advanced device designed to improve how patients self-administer Aspaveli® (pegcetacoplan). The goal of this agreement is to simplify the delivery process, significantly elevating the patient experience.
Enhancing Patient Care with enFuse® Technology
The enFuse Injector is a groundbreaking advancement in drug delivery for patients who need Aspaveli®. It employs cutting-edge technology, enabling discreet, wearable delivery of medication via easy subcutaneous injections that minimize interruptions to daily activities. These enhancements not only provide added convenience but also aim to increase patient confidence and adherence to their therapy.
Insights from Experts on the Collaboration
Lydia Abad-Franch, MD and Sobi's Chief Medical Officer, stressed their commitment to treating rare diseases through this collaboration. The partnership with Enable Injections is anticipated to provide more alternatives for patients, enhance comfort, and ultimately improve overall health outcomes.
Advantages of the enFuse® Injector for Patients
Michael D. Hooven, Chairman and CEO of Enable Injections, also highlighted the promising potential of this collaboration. He mentioned that the partnership could make it easier for patients to access a smoother treatment journey. By simplifying drug delivery, patients can gain more flexibility and freedom in their everyday lives.
Understanding Aspaveli® and Its Significance
Aspaveli® (pegcetacoplan) is an important therapy that targets excessive activation of the complement system, a vital component in various health conditions. This medication is currently approved for treating paroxysmal nocturnal haemoglobinuria (PNH) in several regions worldwide, and research is ongoing to explore its use in other rare diseases.
Strategic Partnership for Wider Reach
Alongside Apellis, Sobi holds global co-development rights for systemic pegcetacoplan. With exclusive commercialization rights outside the U.S., Sobi is well-positioned to optimize the therapeutic potential of pegcetacoplan for treating various unique conditions.
About Enable Injections and Their Commitment
Founded in Cincinnati, Enable Injections is dedicated to revolutionizing drug delivery to significantly enhance patient experiences. Their innovative enFuse® platform is designed to deliver larger volumes of therapies subcutaneously, improving both convenience and health outcomes for patients. This technological progress aligns closely with Sobi’s mission to improve the lives of individuals living with rare diseases.
About Sobi® and Its Global Impact
Sobi® operates as a specialized international biopharmaceutical company that focuses on meeting the needs of patients facing rare and challenging diseases. With about 1,800 employees globally, Sobi is dedicated to ensuring widespread access to innovative treatments in fields such as hematology, immunology, and specialty care. The company’s financial figures demonstrate its significant contribution to the healthcare sector, showing consistent growth and a commitment to enhancing lives.
Frequently Asked Questions
What is the purpose of the partnership between Sobi and Enable Injections?
The partnership is designed to develop and distribute the enFuse® Injector for administering Aspaveli®, ultimately enhancing patient self-administration experiences.
What are the benefits of using the enFuse® Injector?
The enFuse® Injector allows for discreet, wearable subcutaneous drug delivery, minimizing disruptions in patients' daily routines while enhancing convenience.
What is Aspaveli® used for?
Aspaveli® (pegcetacoplan) is a targeted therapy for conditions like paroxysmal nocturnal haemoglobinuria (PNH) and is currently being studied for its potential use in additional rare diseases.
Where is Enable Injections based?
Enable Injections is headquartered in Cincinnati and is committed to healthcare innovation through specialized drug delivery technologies.
What is Sobi®’s mission?
Sobi® aims to transform the lives of individuals with rare and debilitating diseases by ensuring reliable access to innovative medicines and therapeutic solutions.
